REMARKS

Group II was elected. Claim 10 has been amended to better conform to US practice for the elected group. New claims 25-33 were added which depend from elected claim 10. Support for the dependent claims can be found in claims 2-8 and 16 of the application. Claim 10 now requires a TLR 2 and TLR 6 agonis. In contrast to the Pam3-Cys molecule described in Re, which is the TLR 1 / 2 receptor agonist, the bisacyloxypropyl-S-cystein derivative is a molecule having only two fatty acid substitutes and represents a TLR 2 and 6 agonist. Furthermore, in the Example set forth in Re 10 μg/ml of PGN or Pam3-Cys were applied, while according to the present invention 100 pg/ml, i.e., a 100,000 times less concentration, is sufficient for cultivating the dendritic cells.

Claims 1-9, 15, and 23-24 have been canceled without prejudice or disclaimer as being drawn to a non-elected invention. Claims 11-14 have been canceled without prejudice or disclaimer as being drawn to subject matter for which the claim language was objected. The applicant reserves the right to pursue these claims and or claims to additional subject matter supported by the application in one or more continuation or divisional applications.

Claims 19-22 were canceled and are drawn to a Group V invention. However, new claim 38 was added and specifies a process which uses the composition of claim 10 (i.e., claim 38 would be a non-elected Group V invention). Upon allowance of claim 10, the undersigned requests rejoinder of claim 38 to the application.

Claims 16-18 were canceled and are drawn to a Group IV invention. However, new claims 34-37 were added and are drawn to the non-elected Group IV invention. The applicants traverse the restriction requirement between the group II invention and the group IV invention. The Group IV invention species the same interferon gamma receptor agonist and the at least one TLR 2 and TLR 6 agonist as is specified in the elected Group II invention for making the dendritic cells, and the composition of Group IV can be used to make the dendritic cells specified in the Group II invention in vivo. Due to similarities in the specified compound and in its functionality, the Group II and Group IV invention would be classified the same, and there is no undue burden to consider both groups during

examination.

Please proceed to examination on the merits.

A provisional petition is hereby made for any extension of time necessary for the continued pendency during the life of this application. Please charge any fees for such provisional petition and any deficiencies in fees and credit any overpayment of fees to Attorney's Deposit Account No. 50-2041.

Respectfully submitted,



Michael E. Whitham
Reg. No. 32,635

Whitham, Curtis, Christofferson & Cook, P.C.
11491 Sunset Hills Road, Suite 340
Reston, VA 20190

Tel. (703) 787-9400
Fax. (703) 787-7557

Customer No.: 30743